About Cassava Sciences (SAVA)

Visit www.cassavasciences.com for more information about the company

Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a drug for Alzheimer's disease. The Company's products include Simufilam and SavaDx. Its main product Simufilam, is a proprietary oral drug. Simufilam targets an altered form of a protein called filamin A (FLNA) the brain of those with Alzheimer's disease. SavaDx, is an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood and it may possibly detect it years before the overt appearance of clinical symptoms. SavaDx is  a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company's scientific approach for the treatment of Alzheimer's disease seeks to simultaneously progress both neurodegeneration and neuroinflammation. On October 6,2021, Cassava Science announce the start of Phase 3 Clinical trial of Simufilam for the treatment of patients with Alzheimer's disease.